Morgan Stanley raised the firm’s price target on Amrize (AMRZ) to $61 from $60 and keeps an Overweight rating on the shares. Good cash generation, volume growth and margin progression added up to an improved Q3 following a “disappointing” Q2, the analyst tells investors in a post-earnings note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRZ: